Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?

[1]  P. Noseworthy,et al.  Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment , 2021, JAMA network open.

[2]  V. Narayan.  Comparing Cardiovascular Outcomes With Degarelix or Leuprolide as Prostate Cancer Therapy-Applying Real-world Data to Clinical Trial Emulation. , 2021, JAMA Network Open.

[3]  B. Mahal,et al.  Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial , 2021, Cancer.

[4]  F. Saad,et al.  THE CARDIOVASCULAR EFFECTS OF GNRH ANTAGONISTS IN MEN WITH PROSTATE CANCER. , 2021, European heart journal. Cardiovascular pharmacotherapy.

[5]  E. Oger,et al.  Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases , 2020, International journal of cancer.

[6]  J. Kim,et al.  Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study , 2020, Journal of Cancer Research and Clinical Oncology.

[7]  M. Kirby,et al.  Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice , 2020, World Journal of Urology.

[8]  A. Briganti,et al.  Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. , 2020, European urology.

[9]  Deepak L. Bhatt,et al.  Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer , 2020, JACC. CardioOncology.

[10]  M. Hupe,et al.  Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes , 2018, Front. Oncol..

[11]  R. Eckel,et al.  The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. , 2017, Urologic oncology.

[12]  C. Leclercq,et al.  Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data. , 2017, European journal of cancer.

[13]  H. Scher,et al.  Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE−/− mice , 2016, Scientific Reports.

[14]  L. Klotz,et al.  The RADICAL-PC trial. , 2016 .

[15]  N. Keating,et al.  Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. , 2015, European urology.

[16]  L. Klotz,et al.  GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. , 2014, Urologic oncology.

[17]  B. Tombal,et al.  Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. , 2014, European urology.

[18]  Jim C Hu,et al.  Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. , 2011, JAMA.

[19]  L. Klotz,et al.  Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. , 2010, The Journal of urology.

[20]  A. D'Amico,et al.  Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. , 2007, Journal of the National Cancer Institute.